1258221-87-2Relevant academic research and scientific papers
MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF
-
Paragraph 0363, (2021/01/23)
The disclosure relates to compounds and pharmaceutical compositions capable of modulating the hydroxysteroid 17-beta dehydrogenase (HSD17B) family member proteins including inhibiting the HSD17B member proteins, e.g. HSD17B13. The disclosure further relates to methods of treating liver diseases, disorders, or conditions with the compounds and pharmaceutical compositions disclosed herein, in which the HSD17B family member protein plays a role.
Dimethyl-diphenyl-propanamide derivatives as nonsteroidal dissociated glucocorticoid receptor agonists
Yang, Bingwei V.,Weinstein, David S.,Doweyko, Lidia M.,Gong, Hua,Vaccaro, Wayne,Huynh, Tram,Xiao, Hai-Yun,Doweyko, Arthur M.,McKay, Lorraine,Holloway, Deborah A.,Somerville, John E.,Habte, Sium,Cunningham, Mark,McMahon, Michele,Townsend, Robert,Shuster, David,Dodd, John H.,Nadler, Steven G.,Barrish, Joel C.
experimental part, p. 8241 - 8251 (2011/02/21)
A series of 2,2-dimethyl-3,3-diphenyl-propanamides as novel glucocorticoid receptor modulators is reported. SAR exploration led to the identification of 4-hydroxyphenyl propanamide derivatives displaying good agonist activity in GR-mediated transrepressio
